Jobs
-
Pulmatrix has announced the receipt of US patent No. 9,642,798, titled “Monovalent metal cation dry powders for inhalation,” which covers its PUR0200 dry powder formulation of tiotropium bromide for the treatment of COPD. In July… Read more . . .
-
According to intranasal drug developer OptiNose, the company has raised $37 million in a Series D financing round led by Fidelity Management and Research Company. The company said that it plans to use the money… Read more . . .
-
Innovus Pharmaceuticals will launch a fluticasone propionate nasal spray under the brand name FlutiCare in the US by the end of 2017 after acquiring rights to the product from West-Ward Pharmaceuticals International Limited (WWPIL). The… Read more . . .
-
The US Patent and Trademark Office has issued US Patent No. 9,572,774, titled “Dry Powder Vancomycin Compositions and Associated Methods,” to inhaled drug developer Savara, Inc., the company said. In its statement, the company added,… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that data from the real world Salford Lung Study show that asthma patients using Relvar (Breo) Ellipa fluticasone furoate/vilanterol 100/25μg or 200/25μg had improved asthma control compared to those using… Read more . . .
-
Aerosol characterization specialist Proveris Scientific has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an associate member, the company announced. IPAC-RS now has a total of 16 member pharmaceutical companies and… Read more . . .
-
RDD Europe 2017 which took place April 25-28, 2017 at the Palais des Congrès in Antibes, France, drew almost 500 attendees from 32 countries, the largest RDD Europe meeting to date, organizers said. Throughout the… Read more . . .
-
Dauntless Pharmaceutical has announced positive results from a Phase 1 trial of its DP1038 intranasal octreotide acetate, which it is developing for the treatment of acromegaly and neuroendocrine tumors. The company had announced initiation of… Read more . . .
-
Inhaled drug developer Pulmatrix has announced the appointment of former Sunovion Respiratory and CNS Business Unit Head Ted Raad as Chief Business Officer. Raad was most recently Chief Commercial Officer at Option Care, the home… Read more . . .
-
AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris’s inhaled anticalin therapies, Pieris said. In the near… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK